Since 2010, Emmanuel Noumbissie, Founder & CEO, has been immersed in the world of Global Pharmacovigilance, Clinical trials, Active surveillance, Pharmaceutical Products, and Medical devices. As an experienced Epidemiologist, he has contributed to critical projects, including support for NIH’s DAIDS and DMID contracts and the U.S. Army Medical Research and Development.

NEOPha Inc now harnesses the expertise of dedicated professionals who are at the forefront of Data Science, AI services, specializing in areas such as data-driven clinical research activities. Our team excels in a range of critical tasks, including clinical trial designs, protocol development, patient safety monitoring, adverse event reporting, and active surveillance of adverse drug reactions for post-marketed products. We also provide essential services related to the development of policies and guidelines in pharmacovigilance and regulatory affairs, data analysis, and risk-benefit assessment of clinical and non-clinical data. Moreover, we actively contribute to national capacity building, ensuring the supply of approved pharmaceutical products and medical devices, particularly in emerging markets.

Emmanuel established NEOPha in 2010, driven by the mission to advance global pharmacovigilance and improve access to cutting-edge Pharmaceutical products and medical devices through the power of data science and AI.

Since 2022, Emmanuel has forged a strategic partnership with HomeWell Care Services, extending his commitment to providing trustworthy care for your loved ones in the comfort of their own homes, with the same dedication to excellence that defines NEOPha’s work in the field of Data Science and AI for healthcare.